

REVIEW

[View Article Online](#)
[View Journal](#) | [View Issue](#)Cite this: *Nanoscale Adv.*, 2023, 5, 2375

Recent advances in lab-on-a-chip systems for breast cancer metastasis research

Burcu Firatligil-Yildirim, ^a Ozden Yalcin-Ozuysal ^b and Nonappa ^a

Breast cancer is the leading cause of cancer-related deaths in women. Multiple molecular subtypes, heterogeneity, and their ability to metastasize from the primary site to distant organs make breast cancer challenging to diagnose, treat, and obtain the desired therapeutic outcome. As the clinical importance of metastasis is dramatically increasing, there is a need to develop sustainable *in vitro* preclinical platforms to investigate complex cellular processes. Traditional *in vitro* and *in vivo* models cannot mimic the highly complex and multistep process of metastasis. Rapid progress in micro- and nanofabrication has contributed to soft lithography or three-dimensional printing-based lab-on-a-chip (LOC) systems. LOC platforms, which mimic *in vivo* conditions, offer a more profound understanding of cellular events and allow novel preclinical models for personalized treatments. Their low cost, scalability, and efficiency have resulted in on-demand design platforms for cell, tissue, and organ-on-a-chip platforms. Such models can overcome the limitations of two- and three-dimensional cell culture models and the ethical challenges involved in animal models. This review provides an overview of breast cancer subtypes, various steps and factors involved in metastases, existing preclinical models, and representative examples of LOC systems used to study and understand breast cancer metastasis and diagnosis and as a platform to evaluate advanced nanomedicine for breast cancer metastasis.

Received 19th November 2022
Accepted 26th March 2023

DOI: 10.1039/d2na00823h

rsc.li/nanoscale-advances

1. Introduction

Breast cancer is the most frequently diagnosed cancer type and is one of the leading causes of cancer-related deaths among women.^{1,2} According to the latest GLOBOCAN (Global Cancer

Observatory) report, breast cancer is the most common cancer type in 159 out of 185 countries, with ~12% contribution to the total cancer incidence in 2020.³ In most cases, primary breast cancer is curable in around 70–80% of patients if an early-stage diagnosis and treatments are performed. However, intertumoral (*i.e.*, patient-to-patient) and intratumoral (*i.e.*, within a patient's tumor) heterogeneity and multiple molecular subtypes significantly affect breast cancer's prognosis, treatment, and therapeutic outcome.⁴ Gene expression profile approaches have revealed several intrinsic molecular subtypes

^aFaculty of Engineering and Natural Sciences, Tampere University, FI-33720, Tampere, Finland. E-mail: burcu.firatligilyildirim@tuni.fi; nonappa@tuni.fi

^bDepartment of Molecular Biology and Genetics, Izmir Institute of Technology, Urla, 35430, Izmir, Turkey



Burcu Firatligil-Yildirim is a postdoctoral researcher at the Faculty of Engineering and Natural Sciences, Tampere University, Finland. She received her Ph.D. in Molecular Biology and Genetics in 2021 from the Izmir Institute of Technology, Turkey, and M.Sc. in Biomedicine and Biotechnology from the University of Veterinary Medicine, Vienna, Austria. Her research interests

include breast cancer metastasis, lab-on-a-chip platforms, and cell and tissue engineering.



Ozden Yalcin-Ozuysal is an associate professor at the Molecular Biology and Genetics Department, Izmir Institute of Technology, Izmir, Turkey. She received her Ph.D. in 2009 from the Faculty of Biology and Medicine, University of Lausanne, Switzerland. She conducted her postdoctoral research at the École Polytechnique Fédérale de Lausanne. Her research expertise and interests

include breast cancer metastasis, lab-on-a-chip technology, and molecular signaling.



Fig. 1 The mammary gland and molecular subtypes of breast cancer. (a) Schematic representation of the breast duct. (b) Molecular classification of breast cancer subtypes exhibiting their prevalence and associated hormone receptors. (a) was created using <https://Biorender.com>.

of breast cancer (Fig. 1).⁵ Each molecular subtype has different prognosis and metastatic properties (Fig. 1b). This has led to the development of different treatment strategies.⁶ The classification of breast cancer subtypes is related to hormone receptor (estrogen receptor (ER), progesterone receptor (PR), the cell proliferation marker (Ki67), and human epidermal growth factor receptor 2 (HER2)) expression patterns observed in breast cancer cells.⁷ The intrinsic molecular subtypes of breast cancer are categorized as (i) luminal A (ER+/PR+/HER2- and Ki67 low), (ii) luminal B (ER+/PR+/HER2-/+ and Ki67 high), (iii) HER2-enriched (ER-/PR-/HER2+) and (iv) triple negative/basal-like (ER-/PR-/HER2-) (Fig. 1).⁸ The bilayer structure of breast epithelium consists of luminal cells and an outer layer of basal cells surrounded by a basement membrane and stroma. In human breast cancers, although most cases are thought to be of luminal origin,^{9,10} there is still a debate on the origin as both luminal and basal progenitor cells can give rise to different tumor subtypes,¹¹ which increases breast cancer heterogeneity.

Luminal A type has a low-level cellular proliferation with the best prognosis by having low levels of the Ki67 marker. On the other hand, the luminal B type has a higher proliferation rate.^{12,13} The overexpression of the HER2 marker in the HER2-enriched subtype leads to a more aggressive phenotype and worse prognosis than the luminal subtype. The triple-negative breast cancer (TNBC), which is basal-like, is the most aggressive molecular subtype and is observed in 15–20% of all breast cancer cases.^{14,15} TNBC subtype generally shows a higher cellular proliferation rate with a higher risk of metastasis and recurrence.^{16,17} Luminal and HER2-enriched subtypes respond to hormone and HER2- targeted therapies, respectively. On the other hand, there is no specific treatment approach for TNBC that would worsen its prognosis.

2. Breast cancer metastasis

Cancer metastasis is a process in which cancer cells migrate from the primary tumor site to distant organs or secondary sites (Fig. 2).¹⁸ It is a highly complex and multistep process responsible for more than 90% of cancer-associated deaths.¹⁹ Despite substantial advancements in early detection of breast cancer, many patients have metastasis at the time of their first diagnosis.²⁰ Around 50% of the patients first diagnosed with primary breast cancer eventually develop metastasis, leading to poor prognosis.²⁰ In breast cancer, the most prevalent secondary sites are the lung, brain, bone, and liver (Fig. 2). Recent surveillance, epidemiology, and end results (SEER)-based studies revealed that 30–60% of breast cancer patients have metastases in the bone, 21–32% in the lungs, 15–32% in the liver, and 4–10% in the brain.^{21,22}

Importantly, the preferred metastatic sites are often associated with the specific molecular subtype of primary breast cancer.^{23,24} The luminal A and B breast cancer subtypes have the tendency to metastasize to the bone (58.5%). On the other hand,



Nonappa is an Associate Professor at the Faculty of Engineering and Natural Sciences at Tampere University, Finland. He received his Ph.D. in 2008 from the Indian Institute of Science, Bangalore, India. He conducted his postdoctoral research at the University of Jyväskylä and Aalto University, Finland. His research interests include precision nanomaterials, colloids, hydrogels, in vitro breast cancer models,

extracellular matrix design and cryogenic transmission electron microscopy.





Fig. 2 Breast cancer metastatic cascade. Schematic representation of key components involved in breast cancer metastasis from the primary tumor site to secondary target sites- lung, liver, bone, and brain. Figures were created using <https://Biorender.com>.

HER2-enriched breast cancers mainly give rise to liver metastases (31.7% for ER-/PR- and 25.7% for ER+/PR+ cases). Furthermore, HER2-enriched and TNBC subtypes have a higher propensity to metastasize to lung sites compared to HER2-negative breast cancers accounting for 21.2% and 32.1%, respectively. The propensity of different breast cancer subtypes to give rise to different target organ metastases is associated with the microenvironments at primary (breast tissue) and secondary (distant target organ) tumor sites.^{25,26}

The cell-cell and cell-extracellular matrix (ECM) interactions between tumor cells and the microenvironment of distant organs initiate metastatic cascades. The development of metastasis is initiated by migration and local invasion of cancer cells into the surrounding stroma, followed by their intravasation into the vascular system (Fig. 2). Once in blood circulation, some cancer cells adhere to blood vessel walls and extravasate into new cellular surroundings in the target organ site. The cancer cells adapt to and ultimately succeed in the secondary site's foreign or distant environmental conditions to form metastatic colonization.²⁷ Therefore, it is critical to understand the formation of microenvironments for primary and secondary sites and their molecular differences at every stage of breast cancer. This is crucial for the determination of an earlier diagnosis and the development of personalized medicine.²⁸

Current methods such as the Boyden chamber and wound healing assay used to study cancer cell migration, cell invasion and cell-cell interactions are laborious and cost-intensive. Therefore, advanced *in vitro* platforms for understanding disease and providing diagnostic strategies become vital. Early diagnosis of disease at the molecular level using point-of-care

platforms such as microfluidic technology is gaining pivotal preference.²⁹ These emerging bio- and nanotechnological platforms offer more reliable and repeatable approaches with a high throughput screening.³⁰ Point-of-care platforms such as lateral flow tests and chip-based assays have the potential to provide accurate diagnosis and disease monitoring.³¹ More importantly, the combination of biomarkers and microfluidic platforms allows rapid and early detection of molecular mechanisms behind different stages of breast cancer metastasis. Here, we review (i) the current knowledge of how specific components are vital for *in vivo* breast cancer metastasis, (ii) how these components and processes can be mimicked in advanced *in vitro* microfluidic technology, and (iii) how new technologies are used to study and detect different steps of breast cancer metastasis, diagnosis, drug discovery and nanomedicine. Specifically, we will emphasize various lab-on-a-chip (LOC)-based platforms.

2.1. Key players in the breast cancer metastasis cascade

The metastasis of breast cancer cells is closely associated with the microenvironment of the primary and secondary cancer sites. The target site (secondary site) microenvironment is a well-organized site for the colonization of tumor cells and their migration and spreading (Fig. 2). These tumor-induced microenvironments are known as pre-metastatic niches (PMNs).³² The composition and structure of PMNs are complex and different from those of primary tumor regions. Therefore, sufficient interactions between tumor cells and the microenvironment are critical for the survival of tumor cells. This environment consists of an extracellular matrix (ECM), host stromal cells including immune cells such as macrophages, neutrophils

and T-cells, secreted factors (tumor-secreted factors, exosomes, etc.), and proteins such as growth factors, matrix metalloproteinases (MMPs), pro-inflammatory cytokines- S100A8 and S100A9, blood and lymph vessels that make the region inevitable for tumor initiation, progression, and metastasis (Fig. 2).³³ Breast cancer metastasis is a non-random process related to the distribution of breast cancer cells to certain target organs. This phenomenon is known as metastatic organotropism or organ-specific metastasis. It is mediated by several factors, including tumor-intrinsic elements, the communication between tumor cells and the target-site microenvironment, and target organ-specific niches.³⁴ Emerging studies reveal that primary tumor regions not only include cancer cells but also represent an altered surrounding environment. This altered stroma in the primary site called a tumor microenvironment (TME) is one of the key players in tumor initiation, development, and progression. The composition and organization of the extracellular matrix (ECM) and the cellular milieu are critical factors within the TME to foster tumor growth and spread to neighboring or distant sites.³⁵ Therefore, it is decisive to investigate the roles of different cell populations, including immune cells, adipocytes, fibroblasts, and endothelial cells in the breast TME. These components mediate cancer cell dissemination either directly by secreting soluble and non-soluble mediators or indirectly by performing ECM deposition or remodeling.^{36,37}

2.2. Cell-to-cell interactions

One of the main factors regulating the metastatic spread of breast cancer cells is the cooperation between cancer and stromal cells, where chemokine/chemokine receptor interactions play critical roles.³⁸ Different chemokine receptor expression patterns found in breast cancer cells mediate various mechanisms during the metastasis process. For instance, the upregulation of chemokine receptor type 4 (CXCR4) and chemokine receptor type 7 (CCR7) in breast cancer cells is pointedly involved in pseudopodia formation.³⁹ Pseudopodia are membrane protrusions promoting cancer cell dissemination.

This results in chemotactic and invasive responses of breast cancer cells within the body. In addition, the signaling of chemokine receptor type 2 (CXCR2) receptors is essential for the proliferation and colonization of breast cancer cells in the bone.⁴⁰ The source of ligands for the chemokine receptors on breast cancer cells is mainly found within the pre-metastatic niches of their target tissues, which facilitates the movement of cancer cells to the secondary target tissues.³⁸ Specifically, the interactions of stromal cell-derived factor 1 or C-X-C motif chemokine ligand 12 (CXCL12)/CXCR4 for breast cancer metastasis to the lung and C-X-C motif chemokine ligand 5 (CXCL5)/CXCR2 axis for breast cancer colonization in the bone site have been reported.^{38,40}

2.3. The extracellular matrix

The extracellular matrix (ECM) is considered an essential part of both TMEs and PMNs. The ECM is mainly produced and organized by stromal cells residing within it. The ECM provides a dynamic environment that affects cellular responses,

including proliferation, differentiation, and invasion. This dynamic environment is mainly created by biophysical and biochemical properties of the ECM, such as stiffness, topography, and solubility of the matrix and direct or indirect cues regulated by niche-promoting molecular components.⁴¹ Specifically, the niche-promoting protein components of the ECM have been defined as the matrisome, mainly composed of structural ECM proteins, secreted factors, and ECM regulators.^{42,43} The correlation between the increase in the expression of matrisomal components and increased mortality was reported in several studies.⁴⁴ In addition, changes in ECM stiffness and structure have been associated with the alteration of cellular mechanotransduction, which is the conversion of mechanical stimuli into biochemical and cellular responses.^{41,45} These changes have been implied in tumor progression and metastasis.⁴⁶ The stiffness of the ECM can stimulate intracellular signaling pathways to regulate cellular behavior. Breast cancer cells, for instance, can notice the increase in ECM stiffness and react by forming increased traction forces, especially *via* actomyosin and cytoskeleton contractility, promoting their invasion towards the bone microenvironment.⁴⁷ The complex structure represented by the ECM is composed of fibrous proteins, glycoproteins, proteoglycans, and non-proteoglycan polysaccharides. Each component is crucial in providing mechanical strength, promoting cellular migration, and maintaining ECM assembly or cell signaling.⁴⁸ Collagen is the most abundant structural fibrous protein of the ECM. It has several subtypes overexpressed in cancer stem cells (CSCs) and tumor-educated host stromal cells. Cancer progression is facilitated by increased collagen deposition and crosslinking performed by cancer-associated fibroblasts (CAFs) through the activation of focal adhesion kinase (FAK) and YAP/TAZ (transcriptional co-regulators).⁴⁹ Glycoproteins such as fibronectin and laminin are involved in the ECM cohesive network formation by promoting adhesion between cells and ECM components. Other ECM elements, proteoglycans, and polysaccharides play roles in the assembly and buffering of the physical stress of the ECM, respectively.⁴⁸ Overall, the changes in TMEs and PMNs caused by cell–cell and cell–ECM interactions create a charming environment for the survival of cancer cells at secondary sites after their metastasis. The coordinated work between cancer cells and stromal cells, together with their secreted factors and ECM components, opens the gate for the metastasis of breast cancer cells to their target organs. Therefore, to study breast cancer metastasis, *in vitro* models that can mimic these complex heterotypic interactions in metastasis cascades are required.

3. Breast cancer metastasis models

Despite an exponentially increasing number of research papers published on cancer biology, our knowledge of deeply understanding this complex disease is restricted. Investigating the complex physiopathology of the disease is crucial to evaluate anti-cancer drugs and eventually come up with specifically targeted personalized treatments. Several *in vitro* and *in vivo* models ranging from basic two-dimensional (2D) cell culture systems to more complex animal models have been utilized to



Metastasis models	Advantages	Limitations
	Easy to use, low cost, higher reproducibility and no need for specialized personnel and facilities	Highly simplified, inability to test cellular interactions and communications
	High throughput, cell-cell and cell-matrix interactions, represents certain <i>in vivo</i> characteristics	Lack of flow, no perfusion and shear stress
	Representing physiologically relevant conditions, moderate prediction of drug response and resistance	Ethical concerns, high cost, need specialized personnel, facilities, and long-term culture
Lab-on-a-chip	High throughput screening, low consumption, real-time monitoring, control of physical, mechanical and biochemical properties	Difficulty in collecting cells for analyses, limited range of dimensions due to microfabrication limitations

Fig. 3 Comparison of different metastasis models. The advantages and limitations of *in vitro* 2D and 3D culture systems and *in vivo* animal-based models along with lab-on-a-chip platforms, are represented. Images were created using <https://Biorender.com>.

investigate breast cancer metastasis (Fig. 3).⁵⁰ Traditional 2D cell culture systems have long been applied in cancer research. These systems, however, do not accurately mimic physiological circumstances. Therefore, they cannot be translated into clinical approaches. Specifically, in cancer research, 2D models are unable to test heterotypic cell-cell and cell-ECM interactions and communication and, thus, cannot recapitulate the tumor and target site microenvironments.⁵¹ These limitations prompted the development of a three-dimensional (3D) cell culture system. 3D culture models bridge the gaps between 2D systems and animal-based models. The accuracy and flexibility of the cell culture are mainly improved by 3D culture conditions. 3D culture models provide physiologically relevant information by resembling native *in vivo* conditions. Several studies have revealed significant differences in the expression levels of hormone receptors on different breast cancer cells cultured in 2D or 3D culture systems, which consequently led to different responses to targeted and non-targeted chemotherapeutic drugs.⁵²

In vivo tumor characteristics such as dormancy, hypoxia, invasion and apoptotic phenotype, and drug resistance are better mimicked by 3D-cultured breast cancer cells.^{51,52} However, despite having several advantages over 2D and animal models, simple 3D culture systems are limited in their ability to mimic the physiological conditions of the microenvironment since they lack spatiotemporal control. In addition to traditional 3D culture approaches, patient-derived organoids (PDOs) and patient-derived explant culture (PDEC) models have been commonly used as 3D *ex vivo* approaches for studying cancer progression.^{10,53,54} PDOs carry the advantages of both 3D spheroids and primary cell lines representing the information

of the patient.⁵³ Therefore, PDOs can capture the heterogeneity of the parental tumor as well as maintain the genomic and phenotypic features of the tumor of origin, which enables them to become revolutionary preclinical models for personalized medicine.⁵⁴ On the other hand, tissue-specific constraints, requirement for expertise on specific organoid establishment and the need for tissue- and patient-specific efficiency in the establishment and growth of organoids may restrict their use in cancer metastasis and new drug development.

In vivo animal models can serve as alternatives for 2D and 3D systems by overcoming most of the limitations. One of the most studied *in vivo* models in cancer research is patient-derived xenografts (PDXs) involving the implantation of a patient's tumor cells or tissue into immunocompromised mice.⁵⁵ PDXs have been developed as a convenient model, especially for translational cancer research, as they retain the architecture and genomic information of the original tumor. PDX models serve as potential tools for *de novo* identification of molecular mechanisms and drug resistance, identifying new breast cancer biomarkers, and evaluating experimental therapeutic approaches. Yet, PDXs suffer from limitations, including ethical concerns, high cost, and loss of the contribution of human cells to the parental tumor biology due to the invasion of mouse stromal cells over time. PDX models, indeed, mostly represent the TNBC subtype and thus require more improvements in establishing the other molecular subtypes of breast cancer.^{56,57}

The limitations of *in vitro* and *in vivo* models have prompted the development of lab-on-a-chip (LOC) technology as a novel *in vitro* platform. LOC systems offer a more native-like design complexity that can deepen our understanding of breast cancer biology. Being a highly heterogeneous disease whose



progression and dissemination are driven by complex interactions between cellular, genetic and epigenetic factors, breast cancer needs more focused research and a controlled, real-time monitoring provided by LOC technology as a real proxy *in vivo*. Co-culturing tumor and non-tumor cells together with soluble and secreted factors, applicable mechanical features, and rich extracellular matrix (ECM) content is principally encouraged by LOC platforms. Therefore, modeling, monitoring, and investigating the key events of breast cancer progression are well performed in LOC platforms, where they prevail over traditional approaches.

4. Lab-on-a-chip technology in cancer research

Lab-on-a-chip (LOC) technology is a powerful approach that can integrate different functions including the manipulation of samples and their detection and/or quantification in a single platform. LOC systems offer an integrated platform to mimic physiologically relevant conditions by combining microfluidic technology and cell, tissue, or organ culture and therefore, offer opportunities to study complex mechanisms underlying breast cancer and its metastasis using pre-defined architectures and conditions representative of the *in vivo* environment.^{58,59}

LOC has its origin in microfluidics, which allows an extremely low amount of fluid processing using highly controlled microchannels.⁶⁰ LOC technology provides a controlled supply of nutrients, gases, and drugs by laminar flow with a high-throughput screening but low consumption of the reagents.

This advanced technology uses microfluidics science to manipulate fluids at microscale levels within channels that are micrometers in size. Recently, LOC-based *in vitro* platforms have gained considerable attention to study various aspects of breast cancer metastasis (Table 1). Examples include modeling the early stage of breast cancer to investigate molecular players in disease progression,⁶¹ studying cancer immunotherapies to identify new therapeutic approaches,⁶² and mimicking the metastatic cascade to determine critical insights in each step of metastasis.⁶³ The design complexity achieved in LOC platforms offers insights into specific and effective approaches for the treatment of cancer. Recent attempts have also shown that complex architecture, physiologically relevant flow control and real-time 3D imaging offer crucial insights into breast cancer metastasis in co-cultured TNBC-like cell lines. For example, Chi *et al.* introduced a three-layered microfluidic platform called L-TumorChip.⁶⁴ The PDMS-based system allowed the controlled formation and investigation of tumor microvasculature and tumor-stromal microenvironments (Fig. 4a and b).⁶⁴ The L-

Table 1 Lab-on-a-chip (LOC) systems used for breast cancer metastasis research

Applications	Cell types	Approaches	References
Migration and invasions	MCF-7, MDA-MB-231, and SUM-159PT	Subtype-specific invasion of breast cancer cells	Moon <i>et al.</i> ⁶⁷
	MDA-MB-231, breast CAFs, and normal HMFs	The roles of different cellular milieus and ECMs on breast cancer invasion	Lugo-Cintrón <i>et al.</i> ⁶⁸
	Macrophages (RAW 264.7 and MDMs), MDA-MB-231, PC3, and MDA-MB-4355	Macrophage-induced breast cancer cell migration	Li <i>et al.</i> ⁷⁰
Invasion and extravasation	MDA-MB-231, WI-38, BRL3A, and MCF10A	Invasion/chemotaxis preferences to different homing sites	Firatligil-Yildirim <i>et al.</i> ⁷¹
	MDA-MB-231 and hMVECs	Study on steps involved in extravasation	Jeon <i>et al.</i> ⁷³
	MDA-MB-231, hMVECs, hBM-MSC, and osteoblast-differentiated hBM-MSCs	Organ-specific extravasation of breast cancer cells	Jeon <i>et al.</i> ⁷⁴
Modeling metabolic and biochemical properties	MDA-MB-231, HUVECs, and MLO-Y4	The role of mechanical stimuli on breast cancer metastasis to the bone	Mei <i>et al.</i> ⁷⁵
	MDA-MB-231, WI-38, BRL3A, MCF10A, and HUVECs	Extravasation preferences to different homing sites: lung, liver, or breast	Firatligil-Yildirim <i>et al.</i> ⁷¹
	MCF-7	Behavioral changes of breast cancer cells under hypoxic conditions	Grist <i>et al.</i> ⁷⁹
Breast cancer diagnosis and treatment	MCF-10A, MCF-7, MDA-MB-231, HUVECs, and NHLF	Metastasis-related gene expression and extravasation under hypoxic conditions	Song <i>et al.</i> ⁸⁰
	CTCs from HER2-enriched patient samples, AU-565, and RAMOS	Quantification of CTCs in blood samples with a 3D-flow optofluidic chip	Pedrol <i>et al.</i> ⁸⁶
	MCF-7, MDA-MB-231, SK-BR-3, and NFs	Detection of breast cancer derived exosomes	Fang <i>et al.</i> ⁸⁷
Nanomedicine	Blood samples from breast cancer patients	One-step isolation of CTCs by the negative enrichment approach	Lee <i>et al.</i> ⁸⁸
	MCF-7 and ASCs	Evaluation of PDT efficiency in a 3D breast cancer tissue model	Yang <i>et al.</i> ⁹³
	MDA-MB-434	Study and the prediction of nanoparticle distribution in breast cancer tissue	Albanese <i>et al.</i> ⁹⁴
	BT549 and T47D	Nanoparticle-based drug delivery approaches	Chen <i>et al.</i> ⁹⁶





Fig. 4 Representative LOC models used in cancer research. (a) A three-layered microfluidic platform called L-TumorChip in which cancer and endothelial cells were added to the bottom channel within Matrigel and endothelial cells to the top channel. (b) HMVEC mono-layer and cell migration patterns of MDA-MB-231 and HMVEC in L-TumorChip, (I) phase contrast image, (II) CD-31 immunostained images, (III) images of MDA-MB-231 and HMVEC at day 7 with the focal plane at the top channel, (IV) image taken with the focal plane at the bottom chamber, and (V) 3D reconstructed spheroid of MDA-MB-231/HMVEC. Reproduced with permission from ref. 64. (c) The design of a bimodal microfluidic device called PillarX to capture circulating tumor cells (CTCs). The pillar part of the device captures CTCs according to size, while the X part captures due to the EpCAM surface marker. (d) Clusters are trapped in pillars and less cohesive ones pass to the X device to be captured using their surface marker expression levels. Reproduced with permission from ref. 65. (e) Ductal carcinoma *in situ* (DCIS) model to investigate molecular and metabolic breast cancer biology research. The immunotherapies and cell cytotoxicity were studied in the platform using the immune cell recruitment, penetration, and permeability of the solid tumors to therapeutic antibodies. Reproduced with permission from ref. 62 © 2018 Taylor & Francis Group, LLC.

TumorChip offers flow control in a physiologically acceptable range. The top channel was lined with monolayer HMVEC cells and cancer cells encapsulated in Matrigel were filled in the bottom chamber. Controlled cellular communication was mediated *via* the middle porous PDMS membrane. The effects of stromal cells such as normal and cancer-associated fibroblasts (CAFs), endothelial cells and mesenchymal stem cells on the doxorubicin treated MDA-MB-231 cells are investigated.

These approaches collectively represent the system's potential for drug screening, thus leading to the development of new therapeutic drugs.

Ayuso *et al.* developed one of the first LOC-based *in vitro* models that mimics ductal carcinoma *in situ* (DCIS).⁶¹ The design allowed the generation of a hypoxia and nutrient starved microenvironment by DCIS cells which, furthermore, allowed selective targeting of hypoxic DCIS cells. In another study, the same model was used to study natural killer (NK) cell immunotherapies and antibody-dependent cell cytotoxicity using MCF-7 spheroids embedded in a collagen matrix (Fig. 4e).⁶² Nagaraju *et al.* developed a LOC-based vascular model to study the breast cancer metastasis cascade.⁶³ This model revealed an enhanced invasion of MDA-MB-231 cells into the stroma in the presence of vasculature. Microfluidics also allow functionalized architectures with tunable shape, size, and geometry. Such designs can be used for rapid detection of metastatic cells based on their size and mechanical deformation. Green *et al.* recently reported a bimodal microfluidic device called PillarX (Fig. 4c and d).⁶⁵ The design consists of pillared structures for size gradient based isolation and magnetic X-shaped structures for EpCAM gradient based isolation. This device allowed the isolation of single and clusters of CTCs from whole blood samples using functionalized magnetic nanoparticles (Fig. 4c and d). This device efficiently profiles and captures CTCs from whole blood which might be the basis of an effective prognostic tool for cancer.

In the following sections, we highlight the application of LOC platforms for investigating primary and secondary tumor sites and tissue-specific preferences of breast cancer cells and developing precision therapeutics.

5. Lab-on-a-chip technology to study breast cancer metastasis

5.1. Modelling cell migration and invasion

Cell migration and invasion are the key events observed at the beginning of breast cancer progression. Cancer cells possess different dissemination patterns from their primary site, either with individual or collective cell migration mechanisms. These mechanisms are related to various molecular events, including cell-ECM interactions through integrins and cell-cell adhesion and communication mediated by adhesion receptors and gap junctions. The collective cell migration and invasion mechanisms are predominantly observed in breast cancer, especially invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), contributing to its distant metastasis. These cellular dynamics of breast cancer cells are actively regulated by the tumor microenvironment leading to molecular and functional changes within the residing cells. Accordingly, the modulation of the TME in terms of ECM modifications, biochemical and molecular cell parameters, as well as cellular and molecular interactions is one of the key actors driving cancer phenotype and progression.⁶⁶

Therefore, improving breast cancer treatments critically depends on understanding breast cancer progression, the role




Fig. 5 Representative examples showing LOC platforms used to model cell migration and invasion. (a) Schematic representation of the IDC-on-a-chip model used to study subtype-specific invasion potential of breast cancer cells. (b) MCF-7 lumen structure and cross-sectional images in the IDC-on-a-chip platform showing the plasma membrane (magenta), nuclei (blue) and E-cadherin immunostaining (green) of the MCF-7 duct. Reproduced with permission from ref. 67 Copyright: © 2020 Moon *et al.* under the terms of the Creative Commons Attribution License. (c) 3D co-culture model (top) to study the effect of TME on the invasion capacity of MDA-MB-231 cells focusing on fibroblasts and different ECM protein compositions (scale bar: 10 μm) and images (bottom) showing MDA-MB-231 co-cultures with normal fibroblasts, cancer-associated fibroblasts and a collagen I matrix containing fibronectin. (d) Schematics showing cell seeding, media exchanges and imaging after cell migration in a 3D co-culture platform (top) and images showing the effect of ECM on the co-culture of cancer cells (bottom). Reproduced with permission from ref. 68 Copyright © 2020 by the authors under the terms and conditions of the Creative Commons Attribution (CC BY) license. (e) Schematics of a LOC system used to study the role of macrophages in the migration and movements of breast cancer cells. The macrophages (green) and cancer cells (red) were embedded in 3D collagen matrices (orange) to form a suitable TME within the platform. Reproduced with permission from ref. 69 Copyright © 2016 American Association for Cancer Research. (f) Schematics of a LOC system used to study the effect of interstitial flow on macrophage polarization. (g) Fluorescent images showing the interaction of macrophages (top) with the collagen I matrix

of the local tumor microenvironment and subtype-specific characteristics of breast cancer. LOC platforms have been used to investigate the contribution of different cell types, ECM components, chemokines and growth factors to cancer cell migration and invasiveness. Moon *et al.* studied the subtype-specific invasion potential of breast cancer cells using an *in vitro* invasive ductal carcinoma-on-a-chip (IDC-on-a-chip) platform (Fig. 5a and b).⁶⁷ In this mammary duct-mimicking platform, a breast cancer cell duct was formed and surrounded by a 3D collagen matrix. The developed IDC-on-chip model is well suited to mimic cellular growth and local invasion of cell lines corresponding to luminal A subtype (MCF-7) and TNBC subtype (MDA-MB-231 and SUM-159PT). In the platform, TNBC cell lines revealed different invasive characteristics. Notably, higher invasiveness was observed in SUM-159PT cells with collective cell migration and matrix degradation. On the other hand, as expected, MCF-7 showed non-invasive characteristics indicating the capacity of the IDC-on-chip platform to assess subtype-specific invasive characteristics. However, the complexity of the TME was not mimicked to explore the differences in the invasive characteristics of breast cancer cells, especially towards different target sites specific to each subtype. Lugo-Cintrón *et al.* investigated the importance of the TME on the invasion capacity of MDA-MB-231 cells using a 3D microfluidic co-culture system (Fig. 5c and d).⁶⁸ Their study specifically focused on the effect of fibroblasts and different ECM protein compositions on the migration of human breast cancer cell line. MDA-MB-231 cells when co-cultured with breast cancer-associated fibroblasts (CAFs) or normal human mammary fibroblasts (HMFs), showed an increased invasion capacity into the fibronectin-rich collagen matrix compared to the collagen-only control. This study demonstrates the relevance of the platform to observe the contribution of different cellular components and matrix compositions to breast cancer invasion.

Macrophages residing within the tumor microenvironment are the key promoters of cancer cell dissemination. They have been shown to increase cancer cell migration and invasion, especially by enhancing the migration speed and continuity in 3D collagen matrices. Li *et al.* used a microfluidic 3D platform to study how macrophage-secreted TNF- α and TGF β 1 affect the dynamics of cancer cell migration (Fig. 5e).⁶⁹ In this study, the authors used a PDMS-based microfluidic platform and 3D collagen I matrix. Using this platform, the cell migration dynamics of MDA-MB-231, PC3 and MDA-MB-435S cell lines in the presence of macrophages was investigated. It was found that in the presence of Raw 264.7 macrophages as well as primary macrophages such as human monocyte-derived macrophages

(MDM Φ) and murine bone marrow-derived macrophages, cell migration speed and directedness increased in all three cancer cell lines. More importantly, a similar increase in speed and directedness was observed when macrophages were cultured without direct physical contact (but communicated *via* secreted paracrine factors) with cancer cells. Macrophages also upregulated the expression of MMP1 and MT-MMP in cancer cells. The cytokines, TNF- α and TGF β 1, which are released from macrophages to the TME, were identified as the key regulators to enhance the cancer cell migration dynamics including total speed and directedness.

The same LOC platform was also used to mimic the interstitial fluid flow reported in tumors under pathophysiological conditions to study the response of macrophages (Fig. 5f-h).⁷⁰ Interstitial flow is known to affect cancer cell and fibroblast migration. Using this platform, the cell migration dynamics of cancer cells including metastatic breast cancer cell line, MDA-MB-231, were investigated and it was shown that interstitial flow is a critical regulator of immune modulation in the TME. Firatligil-Yildirim *et al.* utilized organ-on-a-chip platforms to investigate the invasion/chemotaxis behavior of TNBC cells (Fig. 5i-l).⁷¹ The modular LOC platform allows the generation of different homing sites including lung, liver and breast microenvironments simulated in a Matrigel matrix. It was shown that MDA-MB-231 TNBC cells preferred to invade the lung site compared to the liver or breast microenvironments. The results indicate the ability of the LOC platform to determine the invasion/chemotaxis phenotype of MDA-MB-231 cells qualitatively and quantitatively.

5.2. Modeling intravasation and extravasation

The complex metastasis process involves the invasion of cancer cells into blood vessels to enter blood circulation, followed by the exit from the circulation at the specific secondary loci (Fig. 2). These intravasation and extravasation steps are mainly directed by the adhesion molecules on the surface of cancer cells that support their attachment to the vascular endothelium.⁷² During each step, cancer cells secrete cytokines to induce vascular hyperpermeability.⁷² This allows the transmigration of cancer cells through the vascular endothelial barrier. Therefore, understanding the mechanisms involved in the breakage of vascular integrity at the primary and secondary loci and how cancer cells can modulate vascular properties is of great interest in developing novel therapeutic approaches. In this sense, different breast tumor-on-chip platforms have been modelled to gain insights into these interconnected processes. Jeon *et al.* investigated the critical steps of extravasation using a three-channel LOC platform (Fig. 6a and b).⁷³ The platform

(scale bar 10 μ m) and quantification of interstitial flow in the LOC system (bottom) using bead tracking (scale bar 50 μ m). (h) Immunofluorescent images showing the effect of flow on the expression of M1 and M2 markers. Reproduced with permission from ref. 70 © 2018 Li *et al.* under the Creative Commons License (<http://creativecommons.org/licenses/by-nc-sa/3.0>). Published by The American Society for Cell Biology. (i and j) Schematics and photogram of the LOC platform used to study breast cancer invasion chemotaxis. The invasion/chemotaxis behaviors of breast cancer cells (red) towards *in vitro* generated homing target sites (represented by black colored homing cells) – lung, liver or breast are shown within the IC-chip platform (scale bar: 5 mm). (k and l) Results showing the ability of the LOC platform to observe the differences in the invasion preferences of breast cancer cells to lung, liver or breast environments. Reproduced with permission from ref. 71 Copyright © 2021 Wiley Periodicals LLC.






Fig. 6 Representative examples showing LOC platforms used to model intravasation and extravasation processes. (a) Schematic representation of the LOC system used for detailed visualization of extravasation steps and the proliferation rate of MDA-MB-231 cells at the collagen matrix after their extravasation across the intact endothelial barrier. (b) Transmigration of cancer cells (green) across the endothelium and extravasation into the collagen matrix (top) and a confocal scan showing different locations of cancer cells (bottom). Reproduced with permission from ref. 73 Copyright © 2013 Jeon *et al.* under the terms of the Creative Commons Attribution License. (c) Schematic representation of the LOC system evaluating the organ-specific extravasation capacity of breast cancer cells into bone-mimicking matrices (top) and real-time monitoring (bottom) of extravasation of cancer cells (red) introduced into the vascular network (HUVECs stained with green). Reproduced with permission from ref. 74 Copyright © 2015 National Academy of Sciences. (d) A human organotypic vascularized model to study breast cancer extravasation and cancer-vascular interactions. (e) Cross-section view of the model mimicking the blood vessel structure with the ECM around it and showing the extravasation of cancer cells across the vessel. (f) Experimental workflow for the BCC extravasation model. Fluorescent images of MDA-MB-231 cells (g) extravasating at 4 h (ii) and 8 h (iii) and (h) taking different morphologies during extravasation such as adhesion to the internal surfaces of the vessel, partial transmigration, and full transmigration out of the vessels (i and ii). Reproduced with permission from ref. 76 Copyright © 2021 Elsevier B.V. (i) In the EX-chip platform, the extravasation capacity of MDA-MB-231 cells to *in vitro* generated lung, liver and bone sites was determined (scale bar: 5 mm). Reproduced with permission from ref. 71 Copyright © 2021 Wiley Periodicals LLC.

allowed the investigation of cancer cell adhesion to the endothelial barrier and their trans-endothelial migration through the vascular monolayer and proliferation at secondary target sites. In their platform, the center channel was used to form an endothelium barrier with human microvascular endothelial

cells (hMVECs). Once an intact monolayer was formed, MDA-MB-231 breast cancer cells were also introduced into the same central channel. The other two channels were used for media supply, and they were connected to the center channel through chambers where 3D collagen-based extracellular space was

formed. This system enabled detailed visualization of extravasation steps and the proliferation rate of MDA-MB-231 cells at the collagen matrix after their extravasation across the intact endothelial barrier. In another study, the same group utilized a 3D microfluidic system to evaluate the organ-specific extravasation of breast cancer cells into *in vitro*-generated microvascularized bone-mimicking matrices (Fig. 6c).⁷⁴ The microvascular network was created within the LOC model with the coculture of endothelial and human bone marrow mesenchymal stem cell-derived (hBM-MSC) mural cells. The coculturing resulted in more branched vascular structures. Besides, osteoblast-differentiated hBM-MSCs were seeded together with the aforementioned cells to form a bone-mimicking microenvironment within the platform. This study revealed a functional *in vitro* model to gain insights into breast cancer extravasation by monitoring the flow, adhesion, and metastasis of metastatic MDA-MB-231 cells through human microvascular networks. Mei *et al.* introduced a metastasis on-a-chip model where breast cancer bone metastasis was mimicked by applying physiologically relevant mechanical stimuli to osteocytes.⁷⁵ Bone fluid flow stimulation, together with the intercellular communication between osteocytes, endothelial cells, and breast cancer cells, was integrated into the platform. The combination enabled physiologically relevant conditions to study the roles of mechanical stimuli in breast cancer bone metastasis. Humayun *et al.* used a PDMS-based LOC platform as a human organotypic vascularized microfluidics model to study breast cancer cell extravasation.⁷⁶ The platform allowed the investigation of cancer-vasculature interactions and the effect of secreted factors during breast cancer cell extravasation (Fig. 6d–h). The results indicated that IL-6, MMP-3 and IL-8 paracrine signaling either independently or in combination induced the disruption of the vascular network, degradation of the basement membrane and cancer cell extravasation. Therefore, the organotypic model has the potential to provide crucial insights on how cancer-vascular interactions are performed for breast cancer cells to extravasate leading to the evaluation of therapeutic agents that prevent cancer extravasation. Firatligil-Yildirim *et al.* investigated the extravasation capacities of MDA-MB-231 cells towards *in vitro* generated lung, liver and breast homing sites in a LOC platform (Fig. 6i).⁷¹ Notably, an intact endothelial monolayer was formed by HUVEC-C cell lines while tissue-specific fibroblasts generated lung, liver and breast target sites. Consistent with the clinical data, MDA-MB-231 cells preferred to extravasate more to the lung microenvironment than to other homing sites providing a relevant platform that can distinguish and determine different metastatic phenotypes of breast cancer cells.

5.3. Modeling metabolic and biochemical properties

Hypoxia, the reduction of oxygen availability, is one of the key stimuli for invasion, metastasis, and drug resistance.⁷⁷ Hypoxia observed within the tumor, especially in solid tumors such as breast cancer, is an effective factor for tumor growth and progression.⁷⁸ Therefore, several lab-on-a-chip platforms were developed to explore the effects of hypoxic conditions on breast

cancer progression and its response to chemotherapeutic drugs. In this context, Grist *et al.* investigated the roles of hypoxia in the behaviors of MCF7 breast cancer cells within 3D spheroids under spatiotemporal oxygen control in a microfluidic system.⁷⁹ The demonstrated LOC platform provided physiologically relevant hypoxia conditions with precise control of oxygen concentration and real-time visualization of cell responses to tunable oxygen profiles. Swelling and shrinking dynamics of tumor spheroids, as well as their ability to uptake the doxorubicin drug during hypoxic exposure (0–10% O₂) were reported. Therefore, the study provides information about the utility and potential of the platform to monitor tumor models under dynamic, time-varying, and/or controlled oxygen conditions during doxorubicin treatment.

Song *et al.* used a lab-on-a-chip platform to evaluate breast cancer extravasation under different oxygen conditions.⁸⁰ MCF10A, MCF-7 and MDA-MB-231 cells were pre-conditioned by hypoxia and then seeded into the microvascular network formed by HUVECs and NHLFs (normal human lung fibroblasts) within the LOC platform. Under hypoxic conditions, breast cancer cells showed increased levels of hypoxia-inducible factor 1 α (HIF-1 α), which triggers cancer progression by regulating the expression of genes for cancer invasion and metastasis.⁸¹ Therefore, the platform used in this study enables the investigation of changes in breast cancer cell morphology and viability as well as their extravasation dynamics and aggressiveness within *in vitro* 3D microvasculature under hypoxia.

5.4. Lab-on-a-chip models for breast cancer diagnosis and treatment

Blood circulation transports circulating tumor cells (CTCs), tumor-derived exosomes, cell-free circulating tumor DNA (ctDNA), and RNA, which are essential for tumor growth and metastasis. Therefore, liquid biopsies have gained attention as they have the potential to identify cancer biomarkers to help in early detection and predicting cancer progression and response to therapies.^{82–85} Several microfluidic platforms have been developed to identify and isolate cancer cells and cancer cell-derived products from liquid biopsies of patients' blood for cancer prognosis and diagnosis. Pedrol *et al.* designed a 3D-flow focusing optofluidic chip to quantify CTCs in blood samples from metastatic HER2 breast cancer (Fig. 7a).⁸⁶ The chip allows the confinement of a single cell in a flow-focusing channel integrated with multiple optical fibers. The microfluidic chip was integrated with single-mode and multimode optical fibers. Single-mode pumping fibers were placed perpendicular to the flow channels and multimode fluorescence collecting fibers were placed at an angle of 45° to the flow channel (Fig. 7b).

The integrated chip allows fluorescence quantification of CTCs from breast cancer liquid samples with signals belonging to HER2 and EpCAM (epithelial cell adhesion molecule) receptors. Using AU-565 (HER2 positive and EpCAM positive) and RAMOS (HER2 negative and EpCAM negative) cell lines it was shown that the results obtained using an integrated optofluidic chip are similar to those obtained in flow cytometry. This type of platform is crucial to define different metastatic degrees






Fig. 7 Representative examples showing LOC platforms used for exosome and CTC isolation from liquid biopsies. (a) Photograph of a 3D flow focusing optofluidic chip. (b) Microscopy image of an optofluidic chip showing irradiating and collecting fibers. Reproduced with permission from ref. 86 Copyright © 2017, Pedrol *et al.* under the terms of the Creative Commons CC BY license. (c) Schematics of multichannel microfluidic chip design for exosome capture and detection and photographs of the microfluidic chip (scale bar 1 cm). Reproduced with permission from ref. 87 Copyright © 2017 Fang *et al.* under the terms of the Creative Commons Attribution License. (d) Schematic diagram showing different compartments and components used in a μ -MixMACS chip for one-step CTC isolation. (e) Fluorescent images of primary breast cancer cells separated using the μ -MixMACS chip with DAPI positive, CD45 negative and pan-cytokeratin positive characteristics. Reproduced with permission from ref. 88 Copyright © 2016 Elsevier B.V.

and progression of real patient samples leading to production of a platform for early monitoring of tumors for early diagnosis.

Fang *et al.* designed a LOC platform to detect breast cancer-derived exosomes from patient plasma using CD63 antibody-conjugated magnetic nanoparticles (Mag-CD63).⁸⁷ The unique multichannel chip consists of immunomagnetic particle collection chambers, mixing channels, inlets and one outlet (Fig. 7c). In this study, three types of breast cancer cell lines; MCF7, MDA-MB-231 and SK-BR-3 were used along with normal fibroblasts (NFs) as a control. The microfluidic device is capable of immunocapturing exosomes under cell culture conditions as well as from patient samples. Furthermore, immunofluorescent staining allowed the detection and quantification of tumor-specific antigens. It was further shown that EpCAM-positive exosomes are higher in breast cancer patient-based plasma compared to healthy control samples. Most of the LOC methods utilize EpCAM to detect CTCs. Due to their heterogeneity and rarity in the bloodstream, the EpCAM-based method may often be unable to capture the whole CTC population and estimate the correct number. In this context, Lee *et al.* demonstrated a one-step isolation of CTCs using an integrated LOC platform (Fig. 7d and e).⁸⁸ Instead of routinely using surface markers and considering the CTC size, they performed the negative

enrichment approach that selectively removes white blood cells (WBCs). The LOC platform consists of a microfluidic mixer to facilitate the interaction between CD45-conjugated magnetic nanoparticles (MNPs) and white blood cells (WBCs), an incubation chamber to stabilize MNP-WBC conjugation and a magnetic-activated cell sorting module to capture MNP-coated WBCs and elute CTCs. Using breast cancer blood samples of patients who received adjuvant therapy, the authors demonstrated that the negative enrichment provided by the integrated platform minimizes any CTC loss during isolation.

5.5. Lab-on-a-chip platforms for nanomedicine

Nanomedicine is an emerging technology that includes the use of nanostructured materials in applications including cancer diagnosis, imaging, targeted drug delivery and therapeutics.⁸⁹ This technology has the power to provide improved bioavailability, direct targeting to diseased cells and dose-response compared to other conventional therapeutic methods.⁹⁰ On the other hand, certain nanoparticles have been shown to have adverse effects by accelerating breast cancer invasion and extravasation when injected intravenously in animal models.⁹¹ Therefore, despite having potential benefits and promising therapeutic benefits in preclinical approaches, nanomedicine



technology needs a more detailed evaluation to achieve clinical success.⁹² LOC platforms have been used to perform a more effective evaluation of nanomaterials to be used in clinical practices.

Yang *et al.* developed an 8-chamber microfluidic system to evaluate the efficiency of gold nanoparticles for photodynamic therapy (PDT) in a 3D breast cancer tissue model (Fig. 8a–c).⁹³ To generate a 3D breast cancer model, breast cancer cells (MCF7) and adipose-derived stromal cells (ASCs) were used. Polyethyleneimine-coated cationic gold nanoparticles (45 ± 12 nm) along with a photosensitizer were injected into the LOC

system with a continuous flow to study the PDT efficiency. After irradiating the breast cancer tissue model containing gold nanoparticles using a broadband light source for 24 h, the distribution profiles of nanoparticles within the tissues and morphological changes were evaluated. This study demonstrates that the microfluidic-based breast cancer model has the potential to provide PDT efficiency evaluation by investigating the flow of nanoparticles and thereby monitoring cancer tissue progression. Albanese *et al.* designed a tumor-on-a-chip platform to investigate the distribution of synthetic carriers within 3D interstitial spaces formed by breast cancer cells embedded



Fig. 8 Examples showing the use of LOC platforms in nanomedicine. (a) Design of an 8-chamber microfluidic platform for photodynamic therapy. (b) Schematics showing 3D breast cancer tissue generation. (c) Schematic image showing the experimental setup of photodynamic therapy evaluation using a 3D breast cancer tissue model formed within the microfluidic platform. Reproduced with permission from ref. 93 Copyright © 2015, Royal Society of Chemistry. (d) Schematic illustration of a tumor-vasculature on-chip (TVOC) model including two layers of microchannels and a membrane between them. The upper channel was designed for modeling 3D tumor vasculature, while the bottom one is for modeling the tumor tissue. (e) A confocal image of a HUVEC monolayer stained with VE-cadherin (red) and nucleus (blue) and microscopy images showing the spheroids in the bottom channel. (f) Design of the top and bottom channels of the TVOC model. The top channel allows for culturing of endothelial cells with steady medium perfusion, while the bottom channel was designed to trap tumor spheroids with its central region. Reproduced with permission from ref. 95 Copyright © 2018 American Chemical Society. (g) Photograph and schematic illustration of a 3D breast cancer-on-chip platform monitoring the transport of nanoparticles. (h) Schematic representation of drug delivery, real-time imaging and cytotoxicity assay. (i) Brightfield and fluorescence images of term culture and spheroid formation inside the chip. Reproduced with permission from ref. 96 Copyright © 2018 Elsevier B.V.

in extracellular matrices.⁹⁴ MDA-MB-435 spheroids were used as a tumor model and fluorescently labelled PEGylated gold nanoparticles of different sizes were used to study tissue accumulation. The 3D cancer tissue microenvironment, the diameters of nanoparticles and their efficiency at targeting receptors

and flow conditions are evaluated. It was shown that the presence of nanoparticles inside the spheroid interstitial space was size dependent, with 40 and 70 nm NPs visible within 10 min. On the other hand, larger NPs were excluded from the interstitial spaces. Furthermore, by comparing passive and active




Fig. 9 Representative examples of multi-organ-on-a-chip (multi-OoC) platforms. (a–c) show approaches to multi-OoC systems based on cell-derived organ mimics and body-on-a-chip (BoC) validation. Reproduced with permission from ref. 98 Copyright: © 2022 Li *et al.* under the terms of the Creative Commons Attribution License. (d) 3D CAD visualization of a metastasis-on-a-chip (MoC) platform, fluid flow overview (C-CRC chamber, Lu-Lung, and E-endothelial), schematics showing sequential patterning and top and side views of MoC. Reproduced with permission from ref. 102 Copyright © 2019 Elsevier B.V. (e) Image of a multi-organ chip (top) designed to study lung cancer metastasis to the brain and its schematic illustration (bottom). (f) Schematic illustrations showing various components and the process used in lung cancer metastasis to the brain. Reproduced with permission from ref. 103 © 2019 Wiley Periodicals, Inc.



targeting, it was found that receptor targeting increased the tissue accumulation of NPs. The *in vitro* results were further supported by intravenously injecting the NPs into a tumor-bearing animal model. The obtained results indicate the accuracy of the platform to study and then predict nanoparticle distribution in breast cancer tissue providing a useful monitoring method for nanoparticles prior to their use in clinics. Wang *et al.* reported a tumor-vasculature-on-a-chip (TVOC) model to study the extravasation and accumulation of nanoparticles and understand the effect of enhanced permeation and retention (EPR). The TVOC platform allowed coculture of HUVECs in its top channels and a bottom channel with human ovarian cancer cell (SKOV3) spheroids. This allowed the creation of an endothelial barrier and a 3D tumor environment with a dense ECM, to study extravasation of 20 and 70 kDa dextran, liposomes, or polymer-based nanoparticles and their accumulation in tumor tissues (Fig. 8d).⁹⁵ The endothelial barrier and dense ECM of tumor sites created in the TVOC model enable the prediction of the transport efficacy of NPs and their tumor accumulation making the microfluidic model powerful for the evaluation of nanoparticles.

Chen *et al.* demonstrated a breast tumor model on a chip having multicellular tumor spheroids, microvessel walls and an ECM to evaluate nanoparticle-based drug delivery approaches (Fig. 8g–i).⁹⁶ The evaluation of the drug delivery system was performed using a functionalized carbon dot-based drug delivery system in TNBC and non-TNBC spheroids generated using BT549 and T47D cell lines, respectively. The system designed by the authors provides real-time monitoring for the transport of nanoparticles across the vessel wall and gives information about their penetration ability into tumor spheroids within the platform. This novel 3D breast-cancer-on-chip platform revealed in the study provides both the real-time dynamic flow of nanoparticles and *in situ* cytotoxicity assessment in a single platform, providing an accurate and cost-effective screening model for better preclinical drug screening.

5.6. Multi-organ-on-chip platforms for breast cancer research

Simple LOC platforms offer cell, tissue or organ specific disease models. However, to understand human physiology, cross-organ communication and complex nature of diseases, advanced multi-organ design is needed. Therefore, multiorgan-on-a-chip (multi-OoC) technology has become one of the important disease models in human health research.⁹⁷ Multi-OoC includes multiple tissues or organs either in a single platform or interconnected individual platforms. The connection of different engineered organ models allows the mimicking of complex human physiology and systemic diseases to develop body-on-a-chip (BOC)-based personalized treatments (Fig. 9).⁹⁸ Beyond disease complexity, multi-OoC allows for better understanding of drug metabolism and therapeutic outcomes.^{99–103} Ronaldson-Bouchard *et al.* developed an interorgan platform in which matured human heart, bone, liver, and skin tissues were formed and connected to each other through a recirculating vascular flow. The design allowed the study of interdependent

organ functions that are typically observed *in vivo*.⁹⁹ In the platform, each tissue was separated by an endothelial barrier that allowed the culture of each tissue under its own optimized culture conditions and the communication between tissues through secreted cytokine, exosomes, and/or circulating cells. These conditions formed in the multi-OoC platform enable the recapitulation of pharmacokinetics (PK)/pharmacodynamics (PD) profiles of doxorubicin and the elaboration of miRNA biomarkers of cardiotoxicity associated with doxorubicin. Therefore, this multi-OoC platform may lead to the development of personalized models for systemic diseases and the testing of new treatments. Another study was performed by Aleman *et al.* where a multi-site metastasis-on-a-chip (MOC) device was explained (Fig. 9d).¹⁰² Different bioengineered 3D organoids including colorectal cancer, liver, lung and endothelial constructs were located in the platform so that they could connect with each other, and fluid flow was applied. Their study showed that colorectal cancer cells grow in their primary site, move to the other chambers where liver and lung constructs are placed and start growing in these target sites under recirculating fluid flow. Importantly, this multi-site MOC platform may lead to the study of detailed molecular mechanisms underlying metastatic preferences of cancer cells in a single platform.

Liu *et al.* introduced a multi-organ microfluidic platform allowing the study of brain metastasis of lung cancer (Fig. 9e and f).¹⁰³ The MOC platform combines a primary tumor (lung cancer) site and metastasis organ (brain) with a functional blood–brain barrier (BBB). Through this approach, the growth at the primary site, extravasation across the BBB, and metastasis to the brain environment were monitored. Different lung cancer cell lines were used to verify the platform and different metastatic capacities were observed among cell lines. More importantly, an elevated expression of the aldo-keto reductase family 1 B10 (AKR1B10) protein was detected in the cells that were being metastasized to the brain parenchyma. Therefore, the introduced multi-organ platform may be used as a feasible approach to studying the pathogenesis of brain metastasis and detecting potential diagnostic biomarkers.

6. Current status and limitations

Lab-on-a-chip platforms developed in recent years have demonstrated great potential as advanced preclinical models for improved diagnosis and personalized therapeutics. This emerging technology offers a physiologically relevant tumor model by providing 3D constructs mimicking *in vivo* tumor microenvironments. Furthermore, it offers the co-culturing of different cell types residing within the TME of the primary tumor and/or PMNs of secondary target sites. The ability of these platforms to monitor cell–cell and/or cell–matrix interactions in real time enables understanding of metastasis phenomena, drug development and screening. Here, some of the recently developed LOC platforms used in monitoring breast cancer progression, identifying the key players contributing to breast cancer metastasis and evaluating their roles in early diagnosis have been discussed. Because of their ability to



mimic the complexity of *in vivo* conditions, LOC platforms allow more realistic, reliable, and accurate models to study the mechanisms underlying breast cancer and its dissemination to a variety of organs. Therefore, these platforms compensate for conventional 2D and 3D *in vitro* models and reduce the need for animal model-based testing for effective anticancer therapies. Due to their design flexibility, LOC platforms can be used from basic research to more complex preclinical and clinical settings. LOC technology is currently incorporated into drug development, disease modeling, preclinical trials, pharmacokinetics, and therapeutics testing. Simpler systems are mainly being used during mid-preclinical trials for the discovery and formulation, while more complex multi-OoC models are required for the prediction of efficacy and toxicity of candidate drugs. Therefore, LOC systems, alone or coupled with an analytical or a mathematical model, provide crucial steps to connect basic science research and clinical studies.

However, it should be addressed that LOC platforms still have several challenges to consider before adapting to clinics. The fabrication of the platforms requires expertise and experienced engineering techniques to develop proper networks and architectures similar to those of tumor physiology. Specifically for LOC platforms considering breast cancer progression, it is challenging to integrate different cell types and tissues for mimicking breast metastatic target sites as most of them need different culture media treatments. Furthermore, the availability of primary cells such as primary breast cancer-associated fibroblasts (CAFs) and tissue samples from breast cancer patients is quite limited which might affect the development of more relevant *in vivo*-like constructs. It is worth noting that there exist challenges to conducting processes such as the detection of cancer-related cells and their separation and isolation along with the analysis within a single platform. Furthermore, one of the main challenges LOC platforms face is the accuracy of these models to predict and identify the human response to existing and/or new anticancer drugs. More extensive collaborations should be performed between different research fields and clinicians to test a large number of patient samples with different molecular signatures to promote the platforms as advanced preclinical tools.

Overall, despite the current challenges, lab-on-a-chip platforms continue to gain more attention regarding their efficiency and applicability for studying breast cancer metastasis and diagnosis leading to the development of personalized medicine by bridging preclinical and clinical approaches.

Author contributions

N. N. and B. F.-Y. together conceived the contents and structure of the review. B. F.-Y. prepared the first version of the manuscript and revised it together with N. N. and O. Y. O. All authors contributed to preparing the final version of the manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors acknowledge the Academy of Finland for project funding (No. 352900) and Flagship on Photonics Research and Innovation (PREIN).

Notes and references

- 1 N. Harbeck, F. Penault-Llorca, J. Cortes, M. Gnant, N. Houssami, P. Poortmans, K. Ruddy, J. Tsang and F. Cardoso, *Nat. Rev. Dis. Primers*, 2019, **5**, 66.
- 2 K. L. Britt, J. Cuzick and K.-A. Phillips, *Nat. Rev. Cancer*, 2020, **20**, 417–436.
- 3 H. Sung, J. Ferlay, R. L. Siegel, M. Laversanne, I. Soerjomataram, A. Jemal and F. Bray, *Ca-Cancer J. Clin.*, 2021, **71**, 209–249.
- 4 F. Lüond, S. Tiede and G. Christofori, *Br. J. Cancer*, 2021, **125**, 164–175.
- 5 F. Andre and L. Pusztai, *Nat. Clin. Pract. Oncol.*, 2006, **3**, 621–632.
- 6 A. Hennigs, F. Riedel, A. Gondos, P. Sinn, P. Schirmacher, F. Marmé, D. Jäger, H.-U. Kauczor, A. Stieber, K. Lindel, J. Debus, M. Golatta, F. Schütz, C. Sohn, J. Heil and A. Schneeweiss, *BMC Cancer*, 2016, **16**, 734.
- 7 C. M. Perou, T. Sørli, M. B. Eisen, M. van de Rijn, S. S. Jeffrey, C. A. Rees, J. R. Pollack, D. T. Ross, H. Johansen, L. A. Akslen, O. Fluge, A. Pergamenschikov, C. Williams, S. X. Zhu, P. E. Lonning, A. L. Børresen-Dale, P. O. Brown and D. Botstein, *Nature*, 2000, **406**, 747–752.
- 8 X. Dai, H. Cheng, Z. Bai and J. Li, *J. Cancer*, 2017, **8**, 3131.
- 9 S. M. Hein, S. Haricharan, A. N. Johnston, M. J. Toneff, J. P. Reddy, J. Dong, W. Bu and Y. Li, *Oncogene*, 2016, **35**, 1461–1467.
- 10 P. M. Munne, L. Martikainen, I. Rätty, K. Bertula, Nonappa, J. Ruuska, H. Ala-Hongisto, A. Peura, B. Hollmann, L. Euro, K. Yavuz, L. Patrikainen, M. Salmela, J. Pokki, M. Kivento, J. Väänänen, T. Suomi, L. Nevalaita, M. Mutka, P. Kovanen, M. Leidenius, T. Meretoja, K. Hukkinen, O. Monni, J. Pouwels, B. Sahu, J. Mattson, H. Joensuu, P. Heikkilä, L. L. Elo, C. Metcalfe, M. R. Junttila, O. Ikkala and J. Klefström, *Nat. Commun.*, 2021, **12**, 6967.
- 11 J. Kim, R. Villadsen, T. Sørli, L. Fogh, S. Z. Grønlund, A. J. Fridriksdottir, I. Kuhn, F. Rank, V. T. Wielenga, H. Solvang, P. A. W. Edwards, A.-L. Børresen-Dale, L. Rønnev-Jessen, M. J. Bissell and O. W. Petersen, *Proc. Natl. Acad. Sci. U. S. A.*, 2012, **109**, 6124–6129.
- 12 G. Ciriello, R. Sinha, K. A. Hoadley, A. S. Jacobsen, B. Reva, C. M. Perou, C. Sander and N. Schultz, *Breast Cancer Res. Treat.*, 2013, **141**, 409–420.
- 13 P. Poudel, G. Nyamundanda, Y. Patil, M. C. U. Cheang and A. Sadanandam, *Breast Cancer Res. Treat.*, 2019, **5**, 21.
- 14 X. Dai, H. Cheng, Z. Bai and J. Li, *J. Cancer*, 2017, **8**, 3131–3141.
- 15 G. K. Malhotra, X. Zhao, H. Band and V. Band, *Cancer Biol. Ther.*, 2010, **10**, 955–960.
- 16 J. R. E. Fernandez, B. L. Eckhardt, J. Lee, B. Lim, T. Pearson, R. S. Seitz, D. R. Hout, B. L. Schweitzer, T. J. Nielsen,



- O. R. Lawrence, Y. Wang, A. Rao and N. T. Ueno, *PLoS One*, 2020, **15**, e0231953.
- 17 P. Zagami and L. A. Carey, *Breast Cancer Res. Treat.*, 2022, **8**, 95.
 - 18 P. S. Steeg, *Nat. Rev. Cancer*, 2016, **16**, 201–218.
 - 19 D. Wirtz, K. Konstantopoulos and P. C. Searson, *Nat. Rev. Cancer*, 2011, **11**, 512–522.
 - 20 A. I. Riggio, K. E. Varley and A. L. Welm, *Br. J. Cancer*, 2021, **124**, 13–26.
 - 21 S. Kimbung, N. Loman and I. Hedenfalk, *Semin. Cancer Biol.*, 2015, **35**, 85–95.
 - 22 M. Yousefi, R. Nosrati, A. Salmaninejad, S. Dehghani, A. Shahryari and A. Saberi, *Cell. Oncol.*, 2018, **41**, 123–140.
 - 23 H. Kennecke, R. Yerushalmi, R. Woods, M. C. Cheang, D. Voduc, C. H. Speers, T. O. Nielsen and K. Gelmon, *J. Clin. Oncol.*, 2010, **28**, 3271–3277.
 - 24 C. Bartmann, M. Wischnewsky, T. Stüber, R. Stein, M. Krockenberger, S. Häusler, W. Janni, R. Kreienberg, M. Blettner, L. Schwentner, A. Wöckel and J. Diessner, *Arch. Gynecol. Obstet.*, 2017, **295**, 211–223.
 - 25 E. Daneberg, H. Bardwell, V. R. T. Zanotelli, E. Provenzano, S.-F. Chin, O. M. Rueda, A. Green, E. Rakha, S. Aparicio, I. O. Ellis, B. Bodenmiller, C. Caldas and H. R. Ali, *Nat. Genet.*, 2022, **54**, 660–669.
 - 26 M.-Z. Jin and W.-L. Jin, *Signal Transduction Targeted Ther.*, 2020, **5**, 166.
 - 27 J. Fares, M. Y. Fares, H. H. Khachfe, H. A. Salhab and Y. Fares, *Signal Transduction Targeted Ther.*, 2020, **5**, 28.
 - 28 N. Pashayan, A. C. Antoniou, U. Ivanus, L. J. Esserman, D. F. Easton, D. French, G. Sroczynski, P. Hall, J. Cuzick, D. G. Evans, J. Simard, M. Garcia-Closas, R. Schmutzler, O. Wegwarth, P. Pharoah, S. Moorthie, S. D. Montgolfier, C. Baron, Z. Herceg, C. Turnbull, C. Balleyguier, P. G. Rossi, J. Wesseling, D. Ritchie, M. Tischkowitz, M. Broeders, D. Reisel, A. Metspalu, T. Callender, H. de Koning, P. Devilee, S. Delaloge, M. K. Schmidt and M. Widschwendter, *Nat. Rev. Clin. Oncol.*, 2020, **17**, 687–705.
 - 29 Y. Manmana, T. Kubo and K. Otsuka, *TrAC, Trends Anal. Chem.*, 2021, **135**, 116160.
 - 30 D. Caballero, S. Kaushik, V. M. Correlo, J. M. Oliveira, R. L. Reis and S. C. Kundu, *Biomaterials*, 2017, **149**, 98–115.
 - 31 A. Joshi, A. Vishnu, T. Sakorikar, A. M. Kamal, J. S. Vaidya and H. J. Pandya, *Nanoscale Adv.*, 2021, **3**, 5542–5564.
 - 32 H. Peinado, H. Zhang, I. R. Matei, B. Costa-Silva, A. Hoshino, G. Rodrigues, B. Psaila, R. N. Kaplan, J. F. Bromberg, Y. Kang, M. J. Bissell, T. R. Cox, A. J. Giaccia, J. T. Erler, S. Hiratsuka, C. M. Ghajar and D. Lyde, *Nat. Rev. Cancer*, 2017, **17**, 302–317.
 - 33 C. F. Monteiro, C. A. Custódio and J. F. Mano, *Adv. Ther.*, 2019, **2**, 1800108.
 - 34 Y. Gao, I. Bado, H. Wang, W. Zhang, J. M. Rosen and X. H.-F. Zhang, *Dev. Cell*, 2019, **49**, 375–391.
 - 35 I. Primac, E. Maquoi, S. Blacher, R. Heljasvaara, J. V. Deun, H. Y. H. Smeland, A. Canale, T. Louis, L. Stuhr, N. E. Sounni, D. Cataldo, T. Pihlajaniemi, C. Pequeux, O. D. Wever, D. Gulberg and A. Noel, *J. Clin. Invest.*, 2019, **129**, 4609–4628.
 - 36 Y. Attieh, A. G. Clark, C. Grass, S. Richon, M. Pocard, P. Mariani, N. Elkhatib, T. Betz, B. Gurchenkov and D. M. Vignjevic, *J. Cell Biol.*, 2017, **216**, 3509–3520.
 - 37 R. Lappano, M. Talia, F. Cirillo, D. C. Rigracciolo, D. Scordamaglia, R. Guzzi, A. M. Miglietta, E. M. D. Francesco, A. Belfiore, A. H. Sims and M. Maggiolini, *J. Exp. Clin. Cancer Res.*, 2020, **39**, 153.
 - 38 B. S. Hill, A. Sarnella, G. D'Avino and A. Zannetti, *Semin. Cancer Biol.*, 2020, **60**, 202–203.
 - 39 A. Muller, B. Homey, H. Soto, N. Ge, D. Catron, M. E. Buchanan, T. McClanahan, E. Murphy, W. Yuan, S. N. Wagner, J. L. Barrera, A. Mohar, E. Verástegui and A. Zlotnik, *Nature*, 2001, **410**, 50–56.
 - 40 R. Romero-Moreno, K. J. Curtis, T. R. Coughlin, M. C. Miranda-Vergara, S. Dutta, A. Natarajan, B. A. Facchine, K. M. Jackson, L. Nystrom, J. Li, W. Kaliney, G. L. Niebur and L. E. Littlepage, *Nat. Commun.*, 2019, **10**, 4404.
 - 41 A. M. Høye and J. T. Erler, *Am. J. Physiol.: Cell Physiol.*, 2016, **310**, C955–C967.
 - 42 A. Naba, K. R. Clauser, S. Hoersch, H. Liu, S. A. Carr and R. O. Hynes, *Mol. Cell. Proteomics*, 2021, **11**, M111.014647.
 - 43 R. O. Hynes and A. Naba, *Cold Spring Harbor Perspect. Biol.*, 2012, **3**, a004903.
 - 44 M. W. Pickup, J. K. Mouw and V. M. Weaver, *EMBO Rep.*, 2014, **15**, 1243–1253.
 - 45 E. K. Paluch, C. M. Nelson, N. Biais, B. Fabry, J. Moeller, B. L. Pruitt, C. Wollnik, G. Kudryasheva, F. Rehfeldt and W. Federle, *BMC Biol.*, 2015, **13**, 47.
 - 46 T. R. Cox and J. T. Erler, *Clin. Cancer Res.*, 2014, **20**, 3637–3643.
 - 47 M. Kalli and T. Stylianopoulos, *Front. Oncol.*, 2018, **8**, 55.
 - 48 S. Nallanthighal, J. P. Heisrman and D.-J. Cheon, *Front. Cell Dev. Biol.*, 2019, **7**, 86.
 - 49 J. Z. Kechagia, J. Ivaska and P. Roca-Cusachs, *Nat. Rev. Mol. Cell Biol.*, 2019, **20**, 457–473.
 - 50 (a) B. Weigelt, J. L. Peterse and L. J. van't Veer, *Nat. Rev. Cancer*, 2005, **5**, 591–602; (b) Y. Imamura, T. Mukohara, Y. Shimono, Y. Funakoshi, N. Chayahara, M. Toyoda, N. Kiyota, S. Takao, S. Kono, T. Nakatsura and H. Minami, *Oncol. Rep.*, 2015, **33**, 1837–1843; (c) J. C. Fontoura, C. Viezzer, F. G. dos Santos, R. A. Ligabue, R. Weinlich, R. D. Puga, D. Antonow, P. Severino and C. Bonorino, *Mater. Sci. Eng., C*, 2020, **107**, 110264.
 - 51 C. Jubelin, J. Muñoz-García, L. Griscom, D. Cochonneau, E. Ollivier, M.-F. Heymann, F. M. Vallette, L. Oliver and D. Heymann, *Cell Biosci.*, 2022, **12**, 155.
 - 52 (a) E. Koedoot, L. Wolters, M. Smid, P. Stoilov, G. A. Burger, B. Herpers, K. Yan, L. S. Price, J. W. M. Martens, S. E. Le Dévédec and B. van de Water, *Sci. Rep.*, 2021, 7259; (b) P. Boix-Montesinos, P. M. Soriano-Teruel, A. Armiñán, M. Orzáez and M. J. Vicent, *Adv. Drug Delivery Rev.*, 2021, **173**, 306–330.
 - 53 L. Liu, L. Yu, Z. Li, W. Li and W. Huang, *J. Transl. Med.*, 2021, **19**, 40.



- 54 J. Wang, C. Chen, L. Wang, M. Xie, X. Ge, S. Wu, Y. He, X. Mou, C. Ye and Y. Sun, *Front. Oncol.*, 2022, **12**, 872531.
- 55 Y. S. DeRose, K. M. Gligorich, G. Wang, A. Georgelas, P. Bowman, S. J. Courdy, A. L. Welm and B. E. Welm, *Curr. Protoc. Pharmacol.*, 2013, **60**, 14.23.1–14.23.43.
- 56 M. D. Matossian, A. A. Giardina, M. K. Wright, S. Elliott, M. M. Loch, K. Nguyen, A. H. Zea, F. H. Lau, K. Moroz, A. I. Riker, S. D. Jones, E. C. Martin, B. A. Bunnell, L. Miele, B. M. Collins-Burow and M. E. Burow, *Women's Health Rep.*, 2020, **1**, 383–392.
- 57 J. R. Whittle, M. T. Lewis, G. J. Lindeman and J. E. Visvader, *Breast Cancer Res.*, 2015, **17**, 17.
- 58 J. El-Ali, P. K. Sorger and K. F. Jensen, *Nature*, 2006, **442**, 403–411.
- 59 J. M. Ayuso, M. Virumbrales-Muñoz, J. M. Lang and D. J. Beebe, *Nat. Commun.*, 2022, **13**, 3086.
- 60 G. M. Whitesides, *Nature*, 2006, **442**, 368–373.
- 61 J. M. Ayuso, A. Gillette, K. Lugo-Cintrón, S. Acevedo-Acevedo, I. Gomez, M. Morgan, T. Heaster, K. B. Wisinski, S. P. Palecek, M. C. Skala and D. J. Beebe, *EBioMedicine*, 2018, **37**, 144–157.
- 62 J. M. Ayuso, R. Truttschel, M. M. Gong, M. Humayun, M. Virumbrales-Munoz, R. Vitek, M. Felder, S. D. Gillies, P. Sondel, K. B. Wisinski, M. Patankar, D. J. Beebe and M. C. Skala, *Oncot Immunology*, 2019, **8**, 1553477.
- 63 S. Nagaraju, D. Truong, G. Mouneimne and M. Nikkhah, *Adv. Healthcare Mater.*, 2018, **7**, 1701257.
- 64 C. W. Chi, Y. H. Lao, A. H. R. Ahmed, E. C. Benoy, C. Li, Z. Dereli-Korkut, B. M. Fu, K. W. Leong and S. Wang, *Adv. Healthcare Mater.*, 2020, **9**, e2000880.
- 65 B. J. Green, M. Marazzini, B. Hershey, A. Fardin, Q. Li, Z. Wang, G. Giangreco, F. Pisati, S. Marchesi, A. Disanza, E. Frittoli, E. Martini, S. Magni, G. V. Bezoussenko, C. Vernieri, R. Lobefaro, D. Parazzoli, P. Maiuri, K. Havas, M. Labib, S. Sigismund, P. P. Di Fiore, R. H. Gunby, S. O. Kelley and G. Scita, *Small*, 2022, **18**, 2206567.
- 66 V. Salvatore, G. Teti, S. Focaroli, M. C. Mazzotti, A. Mazzotti and M. Falconi, *Oncotarget*, 2017, **8**, 9608–9616.
- 67 H. Moon, N. Ospina-Muñoz, V. Noe-Kim, Y. Yang, B. D. Elzey, S. F. Konieczny and B. Han, *PLoS One*, 2020, **15**, e0234012.
- 68 K. M. Lugo-Cintrón, M. M. Gong, J. M. Ayuso, L. A. Tomko, D. J. Beebe, M. Virumbrales-Muñoz and S. M. Ponik, *Cancers*, 2020, **12**, 1173.
- 69 R. Li, J. D. Hebert, T. A. Lee, H. Xing, A. Boussommier-Calleja, R. O. Hynes, D. A. Lauffenburger and R. D. Kamm, *Cancer Res.*, 2017, **77**, 279–290.
- 70 R. Li, J. C. Serrano, H. Xing, T. A. Lee, H. Azizgolshani, M. Zaman and R. D. Kamm, *Mol. Biol. Cell*, 2018, **29**, 1927–1940.
- 71 B. Firatligil-Yildirim, G. Bati-Ayaz, I. Tahmaz, M. Bilgen, D. Pesen-Okvur and O. Yalcin-Ozuysal, *Biotechnol. Bioeng.*, 2021, **118**, 3799–3810.
- 72 A. K. Shenoy and J. Lu, *Mol. Cell. Oncol.*, 2017, **4**, e126067.
- 73 J. S. Jeon, I. K. Zervantonakis, S. Chung, R. D. Kamm and J. L. Charest, *PLoS One*, 2013, **8**, e56910.
- 74 J. S. Jeon, S. Bersini, M. Gilardi, G. Dubini, J. L. Charest, M. Moretti and R. D. Kamm, *Proc. Natl. Acad. Sci. U. S. A.*, 2015, **112**, 214–219.
- 75 X. Mei, K. Middleton, D. Shim, Q. Wan, L. Xu, Y. V. Ma, D. Devadas, N. Walji, L. Wang, E. W. K. Young and L. You, *Integr. Biol.*, 2019, **11**, 119–129.
- 76 M. Humayun, J. M. Ayuso, R. A. Brenneke, M. Virumbrales Muñoz, K. Lugo-Cintrón, S. Kerr, S. M. Ponik and D. J. Beebe, *Biomaterials*, 2021, **270**, 120640.
- 77 R. Wang, I. Godet, Y. Yang, S. Salman, H. Lu, Y. Lyu, Q. Zuo, Y. Want, Y. Zhu, C. Chen, J. He, D. M. Gilkes and G. L. Semenza, *Proc. Natl. Acad. Sci. U. S. A.*, 2021, **118**, e2024490118.
- 78 J. Araos, J. P. Sleeman and B. K. Garvalov, *Clin. Exp. Metastasis*, 2018, **35**, 563–599.
- 79 S. M. Grist, S. S. Nasser, L. Laplantine, J. C. Schmok, D. Yao, J. Hua, L. Chrostowski and K. C. Cheung, *Sci. Rep.*, 2019, **9**, 17782.
- 80 J. Song, A. Miermont, C. T. Lim and R. D. Kamm, *Sci. Rep.*, 2018, **8**, 17949.
- 81 D. M. Gilkes, P. Chaturvedi, S. Bajpai, C. C. Wong, H. Wei, S. Pitcairn, M. E. Hubbi, D. Wirtz and G. L. Semenza, *Cancer Res.*, 2013, **73**, 3285–3286.
- 82 J. C. M. Wan, C. Massie, J. Garcia-Corbacho, F. Mouliere, J. D. Brenton, C. Caldas, S. Pacey, R. Baird and N. Rosenfeld, *Nat. Rev. Cancer*, 2017, **17**, 223–238.
- 83 A. B. Silveira, F.-C. Bidard, M.-L. Tanguy, E. Girard, O. Trédan, C. Dubot, W. Jacot, A. Goncalves, M. Debled, C. Levy, J.-M. Ferrero, C. Jouannaud, M. Rios, M.-A. Mouret-Reynier, F. Dalenc, C. Hego, A. Rampanou, B. Alband, S. Baulande, F. Berger, J. Lemonnier, S. Renault, I. Desmoulins, C. Proudhon and J.-Y. Pierga, *Breast Cancer Res. Treat.*, 2021, **7**, 115.
- 84 C. Alix-Panabieres and K. Pantel, *Clin. Chem.*, 2013, **59**, 110–118.
- 85 C. Alix-Panabieres and K. Pantel, *Lab Chip*, 2014, **14**, 57–62.
- 86 E. Pedrol, M. Garcia-Algar, J. Massons, M. Nazarenus, L. Guerrini, J. Martinez, A. Rodenas, A. Fernandez-Carrascal, M. Aguilo, L. G. Estevez, I. Calvo, A. Olana-Daza, E. Garcia-Rico, F. Diaz and R. A. Alvarez-Puebla, *Sci. Rep.*, 2017, **7**, 3677.
- 87 S. Fang, H. Tian, X. Li, D. Jin, X. Li, J. Kong, C. Yang, X. Yang, Y. Lu, Y. Luo, B. Lin, W. Niu and T. Liu, *PLoS One*, 2017, **12**, e0175050.
- 88 T. Y. Lee, K. Hyun, S. Kim and H. Jung, *Sens. Actuators, B*, 2017, **238**, 1144–1150.
- 89 J. Shi, P. W. Kantoff, R. Wooster and O. C. Farokhzad, *Nat. Rev. Cancer*, 2017, **17**, 20–37.
- 90 R. van der Meel, E. Sulheim, Y. Shi, F. Kiessling, W. J. M. Mulder and T. Lammers, *Nat. Nanotechnol.*, 2019, **14**, 1007–1017.
- 91 F. Peng, M. I. Setyawati, J. K. Tee, X. Ding, J. Wang, M. E. Nga, H. K. Ho and D. T. Leong, *Nat. Nanotechnol.*, 2019, **14**, 279–286.
- 92 Y. S. Zhang, Y.-N. Zhang and W. Zhang, *Drug Discovery Today*, 2017, **22**, 1392–1399.



- 93 Y. Yang, X. Yang, J. Zou, C. Jia, Y. Hu, H. Du and H. Wang, *Lab Chip*, 2015, **15**, 735–744.
- 94 A. Albanese, A. K. Lam, E. A. Sykes, J. V. Rocheleau and W. C. Chan, *Nat. Commun.*, 2013, **4**, 2718.
- 95 H.-F. Wang, R. Ran, Y. Liu, Y. Hui, B. Zeng, D. Chen, D. A. Weitz and C. X. Zhao, *ACS Nano*, 2018, **12**, 11600–11609.
- 96 Y. Chen, D. Gao, Y. Wang, S. Lin and Y. Jiang, *Anal. Chim. Acta*, 2018, **1036**, 97–106.
- 97 N. Picollet-D'hahan, A. Zuhowaska, I. Lemeunier and S. L. Gac, *Trends Biotechnol.*, 2021, **39**, 788–810.
- 98 Z. A. Li and R. S. Tuan, *Stem Cell Res. Ther.*, 2022, **31**, 431.
- 99 K. Ronaldson-Bouchard, D. Teles, K. Yeager, D. N. Tavakol, Y. Zhao, A. Chramiec, S. Tagore, M. Summers, S. Stylianios, M. Tamargo, B. M. Lee, S. P. Halligan, E. H. Abaci, Z. Guo, J. Jackow, A. Pappalardo, J. Shih, R. K. Soni, S. Sonar, C. German, A. M. Christiano, A. Califano, K. K. Hirschi, C. S. Chen, A. Przekwas and G. Vunjak-Novakovic, *Nat. Biomed. Eng.*, 2022, **6**, 351–371.
- 100 A. Herland, B. M. Maoz, D. Das, M. R. Somayaji, R. Prantil-Baun, R. Novak, M. Cronic, T. Huffstater, S. S. F. Jeanty, M. Ingram, A. Chalkiadaki, D. B. Chou, S. Marquez, A. Delahanty, S. Jalili-Firoozinezhad, Y. Milton, A. Sontheimer-Phelps, B. Swenor, O. Levy, K. K. Parker, A. Przekwas and D. E. Ingber, *Nat. Biomed. Eng.*, 2020, **4**, 421–436.
- 101 Z. Li, Z. Lin, S. Liu, H. Yagi, X. Zhang, L. Yocum, M. Romero-Lopez, C. Rhee, M. J. Makarczyk, I. Yu, E. N. Li, M. R. Fritch, Q. Gao, K. B. Goh, B. O'Donnell, T. Hao, P. G. Alexander, B. Mahadik, J. P. Fisher, S. B. Goodman, B. A. Bunnell, R. S. Tuan and H. Lin, *Adv. Sci.*, 2022, **9**, 2105909.
- 102 J. Aleman and A. Skardal, *Biotechnol. Bioeng.*, 2019, **116**, 936–944.
- 103 W. Liu, J. Song, X. Du, Y. Zhou, Y. Li, R. Li, L. Lyu, Y. He, J. Hao, J. Ben, W. Wang, H. Shi and Q. Wang, *Acta Biomater.*, 2019, **91**, 195–208.

